Kyle T. Baron, Pharm.D., Ph.D.

Group Leader PKPD, Principal Scientist II

Kyle joined MetrumRG in 2010 after receiving his Pharm.D. and Ph.D. in Experimental and Clinical Pharmacology from the University of Minnesota. As a member of our translational and systems pharmacology group, Kyle has worked to support sponsor development programs in a variety of therapeutic areas, including chronic hepatitis C infection, HIV, calcium homeostasis and bone health, type-2 diabetes, and cystic fibrosis.

Kyle is the developer and maintainer of mrgsolve (https://mrgsolve.github.io) and also leads workshops at all levels to guide other M&S scientists in the effective use of this simulation tool in PKPD, PBPK, and QSP modeling. Kyle also serves as adjunct faculty in Experimental and Clinical Pharmacology at the University of Minnesota.

Recent publications by this scientist

Population pharmacokinetic modeling of vedolizumab for graft-versus-host disease prophylaxis in adults with Allogeneic Hematopoietic Stem Cell Transplant.

September 5, 2024

This study characterizes the population pharmacokinetics (PK) of vedolizumab in adults undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) for graft-versus-host disease (GvHD) prophylaxis. The analysis identified body weight and albumin levels as significant predictors of vedolizumab clearance, though the covariates studied had no clinically meaningful effect on its overall PK. The findings offer important insights into dosing strategies for vedolizumab in this patient population.

Read Article

bbr.bayes: An Open-Source Tool to Facilitate an Efficient, Reproducible Bayesian Workflow Using NONMEM

July 8, 2024

Presented at PAGE 2024. The bbr.bayes package reduces much of the friction associated with a Bayesian pharmacometrics analysis in NONMEM® and promotes good practice applications.

gPKPDviz: A flexible R shiny tool for pharmacokinetic/pharmacodynamic simulations using mrgsolve

January 12, 2024

GPKPDviz is a Shiny application designed for real-time simulation, visualization, and assessment of PK/PD models. The app allows the generation of virtual populations, simulation of diverse dosing scenarios, and assessment of covariate and dosing regimen impacts on PK/PD endpoints. It supports loading actual population data from clinical trials and offers a streamlined workflow for efficient modeling.

Read Article